Biosimilars in Treatment of Multiple Sclerosis in Iran

Abdorreza Naser Moghadasi ¹ *

Cited by CrossRef: 1

1- Greenberg B, Giovannoni G. A place for biosimilars in the changing multiple sclerosis treatment landscape. Multiple Sclerosis and Related Disorders. 2023;77:104841 [Crossref]

2- Brownlee W, Wolf C, Hartung H, Dingermann T, Anshasi N, Clark R, Trojano M, Selmaj K, Uitdehaag B, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel M, Bobrovnikova O, Cohen J. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Mult Scler. 2022;28(14):2177 [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.